Filtered By:
Drug: Gleevec
This page shows you your search results in order of date.
Order by Relevance | Date
Total 75 results found since Jan 2013.
Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors
Biochim Biophys Acta Mol Basis Dis. 2023 Mar 13:166690. doi: 10.1016/j.bbadis.2023.166690. Online ahead of print.ABSTRACTMost gastrointestinal stromal tumors (GIST) harbor mutated receptor tyrosine kinase (RTK) KIT/PDGFRA, which provides an attractive therapeutic target. However, a majority of GISTs ultimately develop resistance to KIT/PDGFRA inhibitor imatinib, multiple therapeutic targets will be identified as a reasonable strategy in imatinib-resistant GISTs. Biological mechanisms of non-RTK activated CDC42 associated kinase 1 (ACK1) are still unclear, which has been found to be activated in GISTs. In the current report...
Source: Biochimica et Biophysica Acta - March 15, 2023 Category: Biochemistry Authors: Wangzhen He Liangliang Xu Jiongyan Ding Li Song Weili Yang Isabella Klooster Daniel F Pilco-Janeta C ésar Serrano Hongming Fang Guojun Jiang Xiaoyan Wang Jiren Yu Wen-Bin Ou Source Type: research
SPHINX-Based Combination Therapy as a Potential Novel Treatment Strategy for Acute Myeloid Leukaemia
Conclusion: We suggest that specific types of leukaemia may present an opportunity for the development of SRPK1-targeted therapies to be used in combination with established chemotherapeutic drugs.PMID:36895328 | PMC:PMC9988938 | DOI:10.3389/bjbs.2023.11041
Source: British Journal of Biomedical Science - March 10, 2023 Category: Laboratory Medicine Authors: Chigeru Wodi Tareg Belali Ruth Morse Sean Porazinski Michael Ladomery Source Type: research
